Zevra Therapeutics (ZVRA) Current Taxes (2025 - 2026)

Zevra Therapeutics' (ZVRA) quarterly Current Taxes came in at $20.4 million in Q1 2026, up 48.46% on a QoQ basis from $13.7 million in Q4 2025.

Zevra Therapeutics (ZVRA) Current Taxes (2025 - 2026) Analysis & Trends

Zevra Therapeutics (ZVRA) has 2 years of Current Taxes data on file, last reported at $20.4 million in Q1 2026.

Quarterly Current Taxes changed N/A year-over-year to $20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.4 million (changed N/A YoY) and the FY2025 annual result came in at $13.7 million, changed N/A from the prior year.
Current Taxes climbed to $20.4 million in Q1 2026, from $13.7 million in the prior quarter.
In the past five years, Current Taxes ranged from a high of $20.4 million in Q1 2026 to a low of $13.7 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	49.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	76.32 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	59,089.99
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Zevra Therapeutics	671.75 Mn	450.18 Mn	38.18 Mn	20.84 Mn

Download Data